Biotech
GenFleet Therapeutics Announces Potent Anti-tumor Efficacy of GFH375, an Oral KRAS G12D (ON/OFF) Inhibitor, and its Potential in Combination Therapy with RAF/MEK Clamp at 2024 AACR Annual Meeting
2024-04-09 19:00
1024
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today unveiled the latest research findings of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, at the poster presentatio...
GenFleet Therapeutics Announces Broad-spectrum Activity of GFH547, an Oral panRAS (ON) Inhibitor, and Its Potential to Overcome Resistance against SIIP-based KRAS Inhibitors in Late-breaking Research Abstract of 2024 AACR Annual Meeting
2024-04-09 19:00
1341
SHANGHAI and SAN DIEGO, April 9, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the latest findings of GFH547, an oral panRAS (ON) inhibitor, in a late-breaking research abstract at ...
Fiscal Year 2023: Exyte experiences strong growth in Europe and the USA
2024-04-09 17:52
1461
* Sales double in the USA, order intake increases by over 150 percent * More than 50 percent increase in order intake in EMEA * Business Area Technology & Services' sales grow by almost 25 percent * Further improvement in profitability * Exyte CEO Büchele: "Our follow-the-client strategy ...
SeekIn Presents New OncoSeek® Data at the AACR Annual Meeting in San Diego
2024-04-08 20:00
972
Two Sample Types, Three Different Platforms, Six Independent Cohorts of ~12,000 Cancer Patients and Non-cancer Individuals with Diverse Ethnic Backgrounds in Retrospective and Prospective Settings Validate OncoSeek's Ability to Detect Multiple Cancer Types and Predict the Tissue of Origin of Ca...
Seegene and UK Health Security Agency convene a summit to collectively realize "a World Free from All Diseases"
2024-04-08 20:00
1575
* Two CEOs met at Seegene headquarters to discuss and concurred with Seegene's vision * Seegene's swift responses to the COVID-19 pandemic and digital solutions through AI implementation were presented SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Seegene Inc., a leading South Korean comp...
Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
2024-04-08 17:19
1307
-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,600 IU/mL (6.4-fold increase) and approximately 46,000 IU/mL (12-fold increase), respectively -- -- Preliminary Phase I data in target older adult population is on track for H2-2024 -- SHANGHAI, ...
D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline
2024-04-08 15:00
1076
SHANGHAI, April 8, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm. D3 Bio'...
Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial
2024-04-08 08:47
1315
MELBOURNE, Australia, April 8, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK...
Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024
2024-04-08 08:30
920
SHANGHAI and WARREN, N.J., April 7, 2024 /PRNewswire/ -- Laekna (2105.HK) announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster presentation on a clinical trial, at the 2024 Annual Meeting of the American Association for Cancer Research...
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
2024-04-08 07:58
1019
ROCKVILLE, Md. and SUZHOU, China, April 7, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it releases the latest results from three pre...
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
2024-04-05 19:00
1465
ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at th...
IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis
2024-04-05 08:00
1444
SHANGHAI and NANJING, CHINA, and SAN JOSE, Calif., April 4, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, is pleased to announce that the Inve...
Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting
2024-04-04 22:00
1397
BEIJING, April 4, 2024 /PRNewswire/ -- Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, announced that it will present the results of preclinical data of HH018-sesutecan, a tumor microen...
IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR
2024-04-04 21:00
2579
ROME, April 4, 2024 /PRNewswire/ -- IRBM, a leader in the field of drug discovery, announced today that it will be disclosing new data on two of its most promising internal assets at the upcoming American Association for Cancer Research (AACR) Annual Meeting occurring inSan Diego, April 5-10. The...
SYNPET to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024
2024-04-04 01:00
1208
TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based inTaiwan, is proud to announce its participation at the upcoming Petfood Forum 2024. This premier event for pet food and pet treat manufacturers and industry suppliers will ...
Ascletis Announces Strategic Decisions on FXR agonist ASC42
2024-04-03 17:10
1121
HANGZHOU, China and SHAOXING, China, April 3, 2024 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42. After thorough analysis of the Phase II trial data of ASC42 for primary biliary cholangitis (PBC) (...
Tianlong Participated in International Medical Congress of SCO Countries in Kyrgyzstan
2024-04-03 16:16
2109
BISHKEK, Kyrgyzstan, April 3, 2024 /PRNewswire/ -- The International Medical Congress of the SCO countries was held on 27-29 March inBishkek, Kyrgyzstan, under the theme "Innovations and technologies in the development of cardiology and non-communicable diseases in the countries of the Shanghai C...
Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024
2024-04-03 12:00
2037
SINGAPORE, April 3, 2024 /PRNewswire/ -- Great Place To Work®, the global
authority on workplace culture announcedSingapore's top 10 Best Workplaces in
Healthcare and Biopharma™
RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
2024-04-03 11:14
1537
YANTAI, China, April 3, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
I-Mab Announces Closing of the Divestiture of Business Operations in China
2024-04-03 04:01
1232
ROCKVILLE, Md., April 2, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all condition...
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00Most Read
TCTM Filed 2023 Annual Report on Form 20-F
2024-04-20 05:48
3319
Dingdong Files Its Annual Report on Form 20-F
2024-04-20 05:00
3062